Threshold raises $35M

Threshold Pharmaceuticals has raised $35 million from the sale of shares to institutional investors. "Response assessments in over 90 solid tumor patients suggest that TH-302 is active in monotherapy and combination therapy," said CEO Barry Selick, "particularly in patients with metastatic melanoma, refractory lung cancer, soft tissue sarcoma, and pancreatic cancer. The proceeds from this financing will enable the company to generate the additional clinical data required to define and undertake the optimal registration strategy for this very promising drug candidate." Release

Suggested Articles

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.